Cytokinetics (CYTK) reported a quarterly loss of $1.54 per share, beating the Zacks Consensus Estimate by $0.05. This is an improvement from the loss of $1.36 per share a year ago. The company has surpassed EPS estimates three times in the last four quarters.

Despite the positive earnings surprise, Cytokinetics missed revenue estimates, reporting $1.94 million for the quarter compared to the expected $5.57 million. The stock has gained 26.7% this year, outperforming the S&P 500.

Investors are now looking to the company’s earnings outlook for guidance on future performance. Analysts are closely monitoring estimate revisions and the Zacks Rank for insight into potential stock movement.

In a related industry, ANI Pharmaceuticals (ANIP) is set to release its earnings report soon, with expectations of $1.74 per share and $211.32 million in revenue. This represents a 29.9% increase in earnings and a 42.5% increase in revenue from the previous year.

Read more at Yahoo Finance: Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates